| Literature DB >> 33538131 |
Tark Kim1, Seong Yeon Park2, Yee Gyung Kwak3, Jiwon Jung4,5, Min Chul Kim6, Seong Ho Choi6, Shi Nae Yu7, Hyo Lim Hong8, Yong Kyun Kim9,10, Se Yoon Park11, Eun Hee Song12, Ki Ho Park13, Oh Hyun Cho14, Sang Ho Choi15.
Abstract
BACKGROUND: Pyomyositis (PM) is a serious soft tissue infection and despite its clinical importance, previous studies have not been able to fully determine the clinical characteristics and microbial epidemiology of PM in Korea, which we therefore aimed to investigate.Entities:
Keywords: Community; Etiology; Pyomyositis
Year: 2021 PMID: 33538131 PMCID: PMC8032918 DOI: 10.3947/ic.2020.0102
Source DB: PubMed Journal: Infect Chemother ISSN: 1598-8112
Demographics, underlying disease/conditions, and clinical characteristics of patients with community-onset pyomyositis
| Variable | Patients, n (%) | ||||
|---|---|---|---|---|---|
| Total (N = 140) | Community-acquired (n = 102) | Healthcare-associated infectiona (n = 38) | |||
| Demographics | |||||
| Median age, year (IQR) | 58 (45 – 73) | 57 (46 – 70) | 67 (51 – 77) | 0.04 | |
| Sex, male | 81 (57.9) | 61 (59.8) | 20 (52.6) | 0.45 | |
| Underlying diseases or conditions | |||||
| Diabetes mellitus | 47 (33.6) | 30 (29.4) | 17 (47.2) | 0.07 | |
| Solid tumor | 14 (10.0) | 9 (8.8) | 5 (13.9) | 0.52 | |
| Alcoholism | 11 (7.9) | 9 (8.8) | 2 (5.6) | 0.73 | |
| Liver cirrhosis | 8 (5.7) | 7 (6.9) | 1 (2.8) | 0.68 | |
| Immunocompromisedb | 5 (3.6) | 3 (3.0) | 2 (6.3) | 0.59 | |
| End-stage renal disease | 4 (2.9) | 0 | 4 (11.1) | 0.004 | |
| Hematologic malignancy | 2 (1.4) | 0 | 2 (5.6) | 0.07 | |
| Site of infection | |||||
| Lower extremity | 77 (55.0) | 62 (60.8) | 15 (39.5) | 0.04 | |
| Upper extremity | 14 (10.0) | 11 (10.8) | 3 (7.9) | 0.76 | |
| Otherc | 49 ( 35.0) | 29 (28.4) | 20 (52.6) | 0.01 | |
| Severity | |||||
| ICU admission during hospitalization | 34 (24.3) | 18 (17.6) | 16 (43.2) | 0.003 | |
| Septic shock | 17 (12.1) | 11 (10.9) | 6 (16.7) | 0.39 | |
| Laboratory findings at the time of admission, median (IQR) | |||||
| White blood cell count, /mm3 | 12,100 (8,600 – 16,852) | 11,750 (8,482 – 15,117) | 15,170 (10,525 – 20,772) | 0.02 | |
| Platelet count, /mm3 | 234,500 (163,500 – 313,000) | 225,500 (161,750 – 297,000) | 263,000 (146,000 – 368,250) | 0.53 | |
| Creatinine level, mg/dL | 0.8 (0.7 – 1.1) | 0.8 (0.7 – 1.0) | 0.8 (0.7 – 1.3) | 0.19 | |
| C-reactive protein, mg/dL | 12.24 (3.90 – 21.54) | 11.85 (3.17 – 21.64) | 13.6 (7.61 – 20.15) | 0.55 | |
| Surgery | 73 (52.1) | 52 (51.0) | 21 (56.8) | 0.57 | |
| In-hospital mortality | 12 (8.6) | 5 (4.9) | 7 (18.9) | 0.02 | |
aHealthcare-associated infection comprised 28 (20.0%) patients previously admitted within 3 months for more than 2 days before the episode, 17 (12.1%) patients previously receiving intravenous antibiotics, chemotherapy, or nursing care at home within 1 month of the episode, 5 (3.6%) patients who were in a nursing facility, and 3 (2.1%) patients on hemodialysis within 1 month of the episode.
bPatients were deemed immunocompromised if they had human immunodeficiency virus or had acquired immunodeficiency syndrome; or if they had received solid organ or hematopoietic stem-cell transplantation, chemotherapy within 6 weeks, systemic steroids ≥20 mg of prednisone for 2 weeks, or other immunosuppressive agents within 2 weeks before hospitalization.
c25 (17.9%) patients in the paravertebral area, 18 (12.9%) patients in buttock area, 3 (2.1%) patients in the chest wall area, 2 (1.4%) patients in the abdominal wall area, and 1 (7.1%) patient in the face.
IQR, interquartile range; ICU, intensive care unit.
Identified microbial etiologies in patients with community-onset pyomyositis
| Variables | Patients, n (%) | ||||||
|---|---|---|---|---|---|---|---|
| Community-acquired (n = 102) | Healthcare-associated (n = 38) | Total (N = 140)a | |||||
| Any pathogen | 67 (65.7) | 29 (76.3) | 0.31 | 96 (68.6) | |||
| Aerobic Gram-positive organisms | 53 (52.0) | 18 (47.4) | 0.71 | 71 (50.7) | |||
| 31 (30.4) | 7 (18.4) | 0.2 | 38 (27.1) | ||||
| Methicillin-susceptible | 29 (28.4) | 5 (13.2) | 0.08 | 34 (24.3) | |||
| Methicillin-resistant | 2 (2.0) | 2 (5.3) | 0.3 | 4 (2.9) | |||
| Streptococci | 18 (17.6) | 6 (15.8) | >0.99 | 24 (17.1) | |||
| Viridans streptococci | 8 (7.8) | 2 (5.3) | 0.73 | 10 (13.6) | |||
| Group A, C, G streptococci | 4 (3.9) | 2 (5.3) | 0.66 | 6 (4.3) | |||
| Group B streptococci | 6 (5.9) | 2 (5.3) | >0.99 | 8 (5.7) | |||
| Coagulase-negative staphylococci | 4 (3.9) | 0 | 0.57 | 4 (2.9) | |||
| Enterococci | 0 | 4 (10.5) | 0.004 | 4 (2.9) | |||
| Aerobic Gram-negative organisms | 14 (13.7) | 16 (42.1) | <0.001 | 30 (21.4) | |||
| Enteric Gram-negative rod | 14 (13.7) | 13 (34.2) | 0.01 | 27 (19.3) | |||
| 5 (4.9) | 6 (15.8) | 0.07 | 11 (7.9) | ||||
| 6 (5.9) | 1 (2.6) | 0.67 | 7 (5.0) | ||||
| 1 (1.0) | 2 (5.3) | 0.18 | 3 (2.1) | ||||
| 0 | 2 (5.3) | 0.07 | 2 (1.4) | ||||
| 1 (1.0) | 1 (2.6) | 0.47 | 2 (1.4) | ||||
| 1 (1.0) | 1 (2.6) | 0.47 | 2 (1.4) | ||||
| Non-enteric Gram-negative rod | 0 | 4 (10.5) | 0.005 | 4 (2.9) | |||
| 0 | 2 (5.3) | 0.07 | 2 (1.4) | ||||
| 0 | 1 (2.6) | 0.27 | 1 (0.7) | ||||
| 0 | 1 (2.6) | 0.27 | 1 (0.7) | ||||
| Anaerobeb and | 4 (3.9) | 4 (10.5) | 0.21 | 8 (5.7) | |||
| Mycobacterium | 1 (1.0) | 1 (2.6) | 0.47 | 2 (1.4) | |||
aPercentage denominator is the total number of enrolled patients. A total of 111 organisms were isolated from 96 (68.6%) patients, and polymicrobial infections were found in 12 of 96 (12.5%) patients. Microbiologic tests were conducted in 131 (93.6%) patients: 118 for blood culture, 66 for intraoperative specimens, and 55 for aspiration or biopsy. The positive rates of culture according to specimen source were as follows: 78.8% (52/66) from intraoperative specimens, 67.3% (37/55) from aspiration or biopsy specimens, and 28.0% (33/118) from blood cultures.
bThree isolates of Corynebacterium species, one isolate of Bacteroides fragilis, one isolate of Bacillus species, one isolate of Parvimonas micra, one isolate of Lactobacillus.